The expression of commonly studied cytokines such as vascular endothelial growth factor (VEGF), IL-6, and IL-10, were found to correlate with the outcomes of patients with chronic lymphocytic leukaemia (CLL), thus indicating the benefit of using cytokines as biomarkers for treatment efficacy monitoring [7]. This evidence concerns the gene IL6 and B-cell chronic lymphocytic leukemia.